BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38617739)

  • 1. Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer.
    Zhang LT; Zhang Y; Cao BY; Wu CC; Wang J
    World J Gastroenterol; 2024 Mar; 30(12):1739-1750. PubMed ID: 38617739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes.
    Takeda T; Sasaki T; Inoue Y; Okamoto T; Mori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Takahashi Y; Saiura A; Sasahira N
    Pancreatology; 2022 May; 22(4):507-515. PubMed ID: 35422382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early-onset pancreatic cancer: a population-based study using the SEER registry.
    Ansari D; Althini C; Ohlsson H; Andersson R
    Langenbecks Arch Surg; 2019 Aug; 404(5):565-571. PubMed ID: 31377855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and survival in patients with early-onset pancreatic cancer.
    Saadat LV; Chou JF; Gonen M; Soares KC; Kingham TP; Varghese AM; Jarnagin WR; D'Angelica MI; Drebin JA; O'Reilly EM; Wei AC
    Cancer; 2021 Oct; 127(19):3566-3578. PubMed ID: 34228820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demographic, clinical, and pathological features of early onset pancreatic cancer patients.
    Ntala C; Debernardi S; Feakins RM; Crnogorac-Jurcevic T
    BMC Gastroenterol; 2018 Sep; 18(1):139. PubMed ID: 30208959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy.
    Ma N; Wang Z; Zhao J; Long J; Xu J; Ren Z; Jiang G
    Med Sci Monit; 2017 May; 23():2315-2323. PubMed ID: 28512284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data.
    Mendis S; Lipton L; To YH; Ananda S; Michael M; McLachlan SA; Thomson B; Loveday B; Knowles B; Fox A; Nikfarjam M; Usatoff V; Shapiro J; Clarke K; Pattison S; Chee CE; Zielinski R; Wong R; Gibbs P; Lee B
    Br J Cancer; 2024 May; 130(9):1477-1484. PubMed ID: 38448752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis].
    Zhong SJ; Gao JJ; Tang P; Liu YP; Wang SL; Fang H; Qiu JP; Song YW; Chen B; Qi SN; Tang Y; Lu NN; Jing H; Zhai YR; Zhou AP; Bi XG; Ma JH; Li CL; Zhang Y; Shou JZ; Xing NZ; Li YX
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):175-181. PubMed ID: 36781240
    [No Abstract]   [Full Text] [Related]  

  • 16. Survival analysis of 272 patients with pancreatic cancer undergoing combined treatment.
    Cao N; Zhao A; Zhao G; Wang X; Han B; Lin R; Zhao Y; Yang J
    Integr Cancer Ther; 2015 Mar; 14(2):133-9. PubMed ID: 25567328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
    Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
    Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
    Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
    Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.